Streptococcus pneumoniae: Does antimicrobial resistance matter?

Seminars in Respiratory and Critical Care Medicine

Volumn 30, Issue 2, 2009, Pages 210-238

  Lynch III, Joseph P ^a   Zhanel, George G ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Antimicrobial resistance; Invasive pneumococcal disease (IPD); Macrolide resistance; Penicillin resistance; Pneumococcus; Streptococcus pneumoniae

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM; CARBAPENEM; CEFOTAXIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLARITHROMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERTAPENEM; ERYTHROMYCIN; FROPENEM; KETOLIDE; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; ORITAVANCIN; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; PRISTINAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOGRAMIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL MENINGITIS; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; HUMAN; HYPOXEMIA; INTENSIVE CARE UNIT; KIDNEY FAILURE; LOWER RESPIRATORY TRACT INFECTION; MORTALITY; MULTIDRUG RESISTANCE; OTITIS MEDIA; PENICILLIN RESISTANCE; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CALIFORNIA; CANADA; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EVIDENCE-BASED MEDICINE; HUMANS; PENICILLIN RESISTANCE; PENICILLINS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 63149089810     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0029-1202939     Document Type: Review

References (394)

1. Klugman KP. Pneumococcal resistance to antibiotics. Clin Microbiol Rev 1990;3:171-196
2. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992;15:77-83
3. Doern GV, Richter SS, Miller A, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis 2005;41:139-148
4. Lynch JP III, Zhanel GG. Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy. Semin Respir Crit Care Med 2005;26:575-616
5. Jacobs MR, Koornhof HJ, Robins-Browne RM, et al. Emergence of multiply resistant pneumococci. N Engl J Med 1978;299:735-740
6. Hsieh YC, Hsueh PR, Lu CY, Lee PI, Lee CY, Huang LM. Clinical manifestations and molecular epidemiology of necrotizing pneumonia and empyema caused by Streptococcus pneumoniae in children in Taiwan. Clin Infect Dis 2004;38:830-835
7. Doern GV, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001;45:1721-1729
8. Gherardi G, Fallico L, Del Grosso M, et al. Antibiotic-resistant invasive pneumococcal clones in Italy. J Clin Microbiol 2007;45:306-312
9. Farrell DJ, Jenkins SG, Brown SD, Patel M, Lavin BS, Klugman KP. Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance. Emerg Infect Dis 2005;11:851-858
10. Richter SS, Heilmann KP, Coffman SL, et al. The molecular epidemiology of penicillin-resistant Streptococcus pneumoniae in the United States, 1994-2000. Clin Infect Dis 2002;34:330-339
11. Granizo JJ, Aguilar L, Casal J, Garcia-Rey C, Dal-Re R, Baquero F. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979-1997). J Antimicrob Chemother 2000;46:767-773
12. Gay K, Baughman W, Miller Y, et al. The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based assessment. J Infect Dis 2000;182:1417-1424
13. Corso A, Severina EP, Petruk VF, Mauriz YR, Tomasz A. Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States. Microb Drug Resist 1998;4:325-337
14. Widdowson CA, Klugman KP. Emergence of the M phenotype of erythromycin-resistant pneumococci in South Africa. Emerg Infect Dis 1998;4:277-281
15. Kresken M, Henrichfreise B, Bagel S, Brauers J, Wiedemann B. High prevalence of the ermB gene among erythromycin-resistant Streptococcus pneumoniae isolates in Germany during the winter of 2000-2001 and in vitro activity of telithromycin. Antimicrob Agents Chemother 2004;48:3193-3195
16. Brown SD, Farrell DJ, Morrissey I. Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study. J Clin Microbiol 2004;42:4980-4987
17. Alou L, Ramirez M, Garcia-Rey C, Prieto J, de Lencastre H. Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin in Spain: clonal diversity and appearance of ciprofloxacin- resistant epidemic clones. Antimicrob Agents Chemother 2001;45:2955-2957
18. Nichol KA, Zhanel GG, Hoban DJ. Molecular epidemiology of penicillin-resistant and ciprofloxacin-resistant Streptococcus pneumoniae in Canada. Antimicrob Agents Chemother 2003;47:804-808
19. Johnson CN, Benjamin Jr WH Jr, Moser SA, et al. Genetic relatedness of levofloxacin-nonsusceptible Streptococcus pneumoniae isolates from North America. J Clin Microbiol 2003;41:2458-2464
20. Davies TA, Goldschmidt R, Pfleger S, et al. Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000). J Antimicrob Chemother 2003;52:168-175
21. Weiss K, Restieri C, Gauthier R, et al. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. Clin Infect Dis 2001;33:517-522
22. de la Campa AG, Balsalobre L, Ardanuy C, Fenoll A, Perez-Trallero E, Linares J. Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain. Emerg Infect Dis 2004;10:1751-1759
23. Pletz MW, McGee L, Jorgensen J, et al. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother 2004;48:3491-3497
24. Vilhelmsson SE, Kristinsson KG. Stability of penicillin-susceptible and nonsusceptible clones of Streptococcus pneumoniae in southern Sweden. Microb Drug Resist 2007;13:108-113
25. Marimon JM, Perez-Trallero E, Ercibengoa M, Gonzalez A, Fenoll A. Molecular epidemiology and variants of the multidrug-resistant Streptococcus pneumoniae Spain14-5 international clone among Spanish clinical isolates. J Antimicrob Chemother 2006;57:654-660
26. Vanderkooi OG, Low DE, Green K, Powis JE, McGeer A. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005;40:1288-1297
27. Riedel S, Beekmann SE, Heilmann KP, et al. Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 2007;26:485-490
28. Albrich WC, Monnet DL, Harbarth S. Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes. Emerg Infect Dis 2004;10:514-517
29. Syrogiannopoulos GA, Grivea IN, Davies TA, Katopodis GD, Appelbaum PC, Beratis NG. Antimicrobial use and colonization with erythromycin-resistant Streptococcus pneumoniae in Greece during the first 2 years of life. Clin Infect Dis 2000;31:887-893
30. Baquero F. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption? J Chemother 1999;11(Suppl 1):35-43
31. Cizman M, Pokorn M, Seme K, Paragi M, Orazem A. Influence of increased macrolide consumption on macrolide resistance of common respiratory pathogens. Eur J Clin Microbiol Infect Dis 1999;18:522-524
32. Pihlajamaki M, Kotilainen P, Kaurila T, Klaukka T, Palva E, Huovinen P. Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents. Clin Infect Dis 2001;33:483-488
33. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999;341:233-239
34. Bhavnani SM, Hammel JP, Jones RN, Ambrose PG. Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. Diagn Microbiol Infect Dis 2005;51:31-37
35. Van Eldere J, Mera RM, Miller LA, Poupard JA, Amrine-Madsen H. Risk factors for development of multiple-class resistance to Streptococcus pneumoniae strains in Belgium over a 10-year period: antimicrobial consumption, population density, and geographic location. Antimicrob Agents Chemother 2007;51:3491-3497
36. Bergman M, Huikko S, Huovinen P, Paakkari P, Seppala H. Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2006;50:3646-3650
37. Livermore DM, Reynolds R, Stephens P, et al. Trends in penicillin and macrolide resistance among pneumococci in the UK and the Republic of Ireland in relation to antibiotic sales to pharmacies and dispensing doctors. Int J Antimicrob Agents 2006;28:273-279
38. Raz R, Elhanan G, Shimoni Z, et al. Pneumococcal bacteremia in hospitalized Israeli adults: epidemiology and resistance to penicillin. Israeli Adult Pneumococcal Bacteremia Group. Clin Infect Dis 1997;24:1164-1168
39. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997. Am J Med 1999;107(1A):34S-43S
40. Rahav G, Toledano Y, Engelhard D, et al. Invasive pneumococcal infections: a comparison between adults and children. Medicine (Baltimore) 1997;76:295-303
41. Waterer GW, Buckingham SC, Kessler LA, Quasney MW, Wunderink RG. Decreasing beta-lactam resistance in pneumococci from the Memphis region: analysis of 2,152 isolates From 1996 to 2001. Chest 2003;124:519-525
42. Catalan MJ, Fernandez JM, Vazquez A, Varela de Seijas E, Suarez A, Bernaldo de Quiros JC. Failure of cefotaxime in the treatment of meningitis due to relatively resistant Streptococcus pneumoniae. Clin Infect Dis 1994;18:766-769
43. Sloas MM, Barrett FF, Chesney PJ, et al. Cephalosporin treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J 1992;11:662-666
44. Dagan R, Abramson O, Leibovitz E, et al. Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of acute otitis media? J Infect Dis 1997;176:1253-1259
45. del Castillo F, Baquero-Artigao F, Garcia-Perea A. Influence of recent antibiotic therapy on antimicrobial resistance of Streptococcus pneumoniae in children with acute otitis media in Spain. Pediatr Infect Dis J 1998;17:94-97
46. Jacobs MR. Increasing importance of antibiotic-resistant Streptococcus pneumoniae in acute otitis media. Pediatr Infect Dis J 1996;15:940-943
47. Poole MD. Otitis media complications and treatment failures: implications of pneumococcal resistance. Pediatr Infect Dis J 1995;14(4, Suppl):S23-S26
48. Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000;90:223-229
49. Metlay JP, Hofmann J, Cetron MS, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000;30:520-528
50. Pallares R, Gudiol F, Linares J, et al. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. N Engl J Med 1987;317:18-22
51. Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995;333:474-480
52. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003;37:230-237
53. Lynch JP III, Martinez FJ. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin Infect Dis 2002;34(Suppl 1):S27-S46
54. Waterer GW, Wunderink RG, Jones CB. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest 2000;118:1839-1840
55. Kelley MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000;31:1008-1011
56. Fogarty C, Goldschmidt R, Bush K. Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis 2000;31:613-615
57. Lonks JR. What is the clinical impact of macrolide resistance? Curr Infect Dis Rep 2004;6:7-12
58. Low DE. Quinolone resistance among pneumococci: therapeutic and diagnostic implications. Clin Infect Dis 2004;38(Suppl 4):S357-S362
59. Low DE. Fluoroquinolone-resistant pneumococci: maybe resistance isn't futile? Clin Infect Dis 2005;40:236-238
60. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346:747-750
61. Urban C, Rahman N, Zhao X, et al. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J Infect Dis 2001;184:794-798
62. Aspa J, Rajas O, Rodriguez de Castro F, et al. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis 2004;38:787-798
63. Henriques B, Kalin M, Ortqvist A, et al. Molecular epidemiology of Streptococcus pneumoniae causing invasive disease in 5 countries. J Infect Dis 2000;182:833-839
64. Song JH, Jung SI, Ki HK, et al. Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in Asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens. Clin Infect Dis 2004;38:1570-1578
65. Friedland IR. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatr Infect Dis J 1995;14:885-890
66. Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004;170:440-444
67. Turett GS, Blum S, Fazal BA, Justman JE, Telzak EE. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis 1999;29:321-327
68. Neuman MI, Kelley M, Harper MB, File TM Jr, Camargo CA Jr. Factors associated with antimicrobial resistance and mortality in pneumococcal bacteremia. J Emerg Med 2007;32:349-357
69. Ewig S, Ruiz M, Torres A, et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 1999;159:1835-1842
70. Karlowsky JA, Thornsberry C, Jones ME, Evangelista AT, Critchley IA, Sahm DF. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin Infect Dis 2003;36:963-970
71. Johnson CN, Briles DE, Benjamin WH Jr, Hollingshead SK, Waites KB. Relative fitness of fluoroquinolone-resistant Streptococcus pneumoniae. Emerg Infect Dis 2005;11:814-820
72. Smith AM, Feldman C, Massidda O, McCarthy K, Ndiweni D, Klugman KP. Altered PBP 2A and its role in the development of penicillin, cefotaxime, and ceftriaxone resistance in a clinical isolate of Streptococcus pneumoniae. Antimicrob Agents Chemother 2005;49:2002-2007
73. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Tenth informational supplement, M100-S11. Wayne, PA: National Committee for Clinical Laboratory Standards; 2001
74. Kosowska K, Jacobs MR, Bajaksouzian S, Koeth L, Appelbaum PC. Alterations of penicillin-binding proteins 1A, 2X, and 2B in Streptococcus pneumoniae isolates for which amoxicillin MICs are higher than penicillin MICs. Antimicrob Agents Chemother 2004;48:4020-4022
75. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003;52:229-246
76. Sahm DF, Thornsberry C, Mayfield DC, Jones ME, Karlowsky JA. In vitro activities of broad-spectrum cephalosporins against nonmeningeal isolates of Streptococcus pneumoniae: MIC interpretation using NCCLS M100-S12 recommendations. J Clin Microbiol 2002;40:669-674
77. Ruhe JJ, Myers L, Mushatt D, Hasbun R. High-level penicillin- nonsusceptible Streptococcus pneumoniae bacteremia: identification of a low-risk subgroup. Clin Infect Dis 2004;38:508-514
78. Appelbaum PC. World-wide development of antibiotic resistance in pneumococci. Eur J Clin Microbiol 1987;6:367-377
79. Appelbaum PC. Epidemiology and in vitro susceptibility of drug-resistant Streptococcus pneumoniae. Pediatr Infect Dis J 1996;15:932-934
80. Bedos JP, Chevret S, Chastang C, Geslin P, Regnier B. Epidemiological features of and risk factors for infection by Streptococcus pneumoniae strains with diminished susceptibility to penicillin: findings of a French survey. Clin Infect Dis 1996;22:63-72
81. Kam KM, Luey KY, Fung SM, Yiu PP, Harden TJ, Cheung MM. Emergence of multiple-antibiotic-resistant Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1995;39:2667-2670
82. Lee HJ, Park JY, Jang SH, Kim JH, Kim EC, Choi KW. High incidence of resistance to multiple antimicrobials in clinical isolates of Streptococcus pneumoniae from a university hospital in Korea. Clin Infect Dis 1995;20:826-835
83. Song JH, Lee NY, Ichiyama S, et al. Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study. Clin Infect Dis 1999;28:1206-1211
84. Doern GV, Brueggemann A, Holley HP Jr, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996;40:1208-1213
85. Doern GV, Brueggemann AB, Blocker M, et al. Clonal relationships among high-level penicillin-resistant Streptococcus pneumoniae in the United States. Clin Infect Dis 1998;27:757-761
86. Doern GV, Brueggemann AB, Huynh H, Wingert E. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997 98. Emerg Infect Dis 1999;5:757-765
87. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000;343:1917-1924
88. Thornsberry C, Jones ME, Hickey ML, Mauriz Y, Kahn J, Sahm DF. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998. J Antimicrob Chemother 1999;44:749-759
89. Deeks SL, Palacio R, Ruvinsky R, et al. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. The Streptococcus pneumoniae Working Group. Pediatrics 1999;103:409-413
90. Schrag SJ, McGee L, Whitney CG, et al. Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin. Antimicrob Agents Chemother 2004;48:3016-3023
91. Zhanel GG, Palatnick L, Nichol KA, Bellyou T, Low DE, Hoban DJ. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003;47:1867-1874
92. Pallares R, Capdevila O, Linares J, et al. The effect of cephalosporin resistance on mortality in adult patients with nonmeningeal systemic pneumococcal infections. Am J Med 2002;113:120-126
93. Karlowsky JA, Jones ME, Draghi DC, Sahm DF. Clinical isolates of Streptococcus pneumoniae with different susceptibilities to ceftriaxone and cefotaxime. Antimicrob Agents Chemother 2003;47:3155-3160
94. Smith AM, Klugman KP. Alterations in MurM, a cell wall muropeptide branching enzyme, increase high-level penicillin and cephalosporin resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2001;45:2393-2396
95. Munoz R, Dowson CG, Daniels M, et al. Genetics of resistance to third-generation cephalosporins in clinical isolates of Streptococcus pneumoniae. Mol Microbiol 1992;6:2461-2465
96. Doern GV, Pfaller MA, Kugler K, Freeman J, Jones RN. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis 1998;27:764-770
97. Nichol KA, Zhanel GG, Hoban DJ. Penicillin-binding protein 1A, 2B, and 2X alterations in Canadian isolates of penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 2002;46:3261-3264
98. du Plessis M, Bingen E, Klugman KP. Analysis of penicillin-binding protein genes of clinical isolates of Streptococcus pneumoniae with reduced susceptibility to amoxicillin. Antimicrob Agents Chemother 2002;46:2349-2357
99. Coffey TJ, Daniels M, McDougal LK, Dowson CG, Tenover FC, Spratt BG. Genetic analysis of clinical isolates of Streptococcus pneumoniae with high-level resistance to expanded-spectrum cephalosporins. Antimicrob Agents Chemother 1995;39:1306-1313
100. Chiu CH, Su LH, Huang YC, et al. Increasing ceftriaxone resistance and multiple alterations of penicillin-binding proteins among penicillin-resistant Streptococcus pneumoniae isolates in Taiwan. Antimicrob Agents Chemother 2007;51:3404-3406
101. McDougal LK, Rasheed JK, Biddle JW, Tenover FC. Identification of multiple clones of extended-spectrum cephalosporin-resistant Streptococcus pneumoniae isolates in the United States. Antimicrob Agents Chemother 1995;39:2282-2288
102. Waites K, Brown S. Antimicrobial resistance among isolates of respiratory tract infection pathogens from the southern United States: data from the PROTEKT US surveillance program 2000/2001. South Med J 2003;96:974-985
103. Karlowsky JA, Thornsberry C, Critchley IA, et al. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. Antimicrob Agents Chemother 2003;47:1790-1797
104. Jones ME, Blosser-Middleton RS, Thornsberry C, Karlowsky JA, Sahm DF. The activity of levofloxacin and other antimicrobials against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999-2002. Diagn Microbiol Infect Dis 2003;47:579-586
105. Dias R, Louro D, Canica M. Antimicrobial susceptibility of invasive Streptococcus pneumoniae isolates in Portugal over an 11-year period. Antimicrob Agents Chemother 2006;50:2098-2105
106. Song JH, Jung SI, Ko KS, et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother 2004;48:2101-2107
107. Brandileone MC, Casagrande ST, Guerra ML, Zanella RC, Andrade AL, Di Fabio JL. Increase in numbers of beta-lactam-resistant invasive Streptococcus pneumoniae in Brazil and the impact of conjugate vaccine coverage. J Med Microbiol 2006;55(Pt 5):567-574
108. Critchley IA, Brown SD, Traczewski MM, Tillotson GS, Janjic N. National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. Antimicrob Agents Chemother 2007;51:4382-4389
109. Zhanel GG, Wang X, Nichol K, et al. Molecular characterisation of Canadian paediatric multidrug-resistant Streptococcus pneumoniae from 1998-2004. Int J Antimicrob Agents 2006;28:465-471
110. Finkelstein JA, Huang SS, Daniel J, et al. Antibiotic-resistant Streptococcus pneumoniae in the heptavalent pneumococcal conjugate vaccine era: predictors of carriage in a multicommunity sample. Pediatrics 2003;112:862-869
111. Nuorti JP, Butler JC, Crutcher JM, et al. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. N Engl J Med 1998;338:1861-1868
112. Nava JM, Bella F, Garau J, et al. Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: a population-based study. Clin Infect Dis 1994;19:884-890
113. Choi EH, Lee HJ. Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children. Clin Infect Dis 1998;26:1346-1354
114. Koornhof HJ, Wasas A, Klugman K. Antimicrobial resistance in Streptococcus pneumoniae: a South African perspective. Clin Infect Dis 1992;15:84-94
115. Albanese BA, Roche JC, Pass M, Whitney CG, McEllistrem MC, Harrison LH. Geographic, demographic, and seasonal differences in penicillin-resistant Streptococcus pneumoniae in Baltimore. Clin Infect Dis 2002;34:15-21
116. Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995;333:481-486
117. Crewe-Brown HH, Karstaedt AS, Saunders GL, et al. Streptococcus pneumoniae blood culture isolates from patients with and without human immunodeficiency virus infection: alterations in penicillin susceptibilities and in serogroups or serotypes. Clin Infect Dis 1997;25:1165-1172
118. Pemba L, Charalambous S, von Gottberg A, et al. Impact of cotrimoxazole on non-susceptibility to antibiotics in Streptococcus pneumoniae carriage isolates among HIV-infected mineworkers in South Africa. J Infect 2008;56:171-178
119. Meynard JL, Barbut F, Blum L, et al. Risk factors for isolation of Streptococcus pneumoniae with decreased susceptibility to penicillin G from patients infected with human immunodeficiency virus. Clin Infect Dis 1996;22:437-440
120. Sa-Leao R, Tomasz A, Sanches IS, et al. Carriage of internationally spread clones of Streptococcus pneumoniae with unusual drug resistance patterns in children attending day care centers in Lisbon, Portugal. J Infect Dis 2000;182:1153-1160
121. Ronchetti MP, Guglielmi F, Latini L, et al. Resistance patterns of Streptococcus pneumoniae from children in central Italy. Eur J Clin Microbiol Infect Dis 1999;18:376-379
122. Brueggemann AB, Coffman SL, Rhomberg P, et al. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob Agents Chemother 2002;46:680-688
123. Hamilton-Miller JM, Shah S. Comparative in-vitro activity of ketolide HMR 3647 and four macrolides against gram-positive cocci of known erythromycin susceptibility status. J Antimicrob Chemother 1998;41:649-653
124. Jalava J, Kataja J, Seppala H, Huovinen P. In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species. Antimicrob Agents Chemother 2001;45:789-793
125. Reinert RR, Bryskier A, Lutticken R. In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany. Antimicrob Agents Chemother 1998;42:1509-1511
126. Marton A. Pneumococcal antimicrobial resistance: the problem in Hungary. Clin Infect Dis 1992;15:106-111
127. Mason EO Jr, Lamberth LB, Kershaw NL, Prosser BL, Zoe A, Ambrose PG. Streptococcus pneumoniae in the USA: in vitro susceptibility and pharmacodynamic analysis. J Antimicrob Chemother 2000;45:623-631
128. Latini L, Ronchetti MP, Merolla R, et al. Prevalence of mefE, erm and tet(M) genes in Streptococcus pneumoniae strains from Central Italy. Int J Antimicrob Agents 1999;13:29-33
129. Arrieta A, Arguedas A, Fernandez P, et al. High-dose azithromycin versus high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent acute otitis media. Antimicrob Agents Chemother 2003;47:3179-3186
130. Reichler MR, Rakovsky J, Slacikova M, et al. Spread of multidrug-resistant Streptococcus pneumoniae among hospitalized children in Slovakia. J Infect Dis 1996;173:374-379
131. Moreno S, Garcia-Leoni ME, Cercenado E, Diaz MD, Bernaldo de Quiros JC, Bouza E. Infections caused by erythromycin-resistant Streptococcus pneumoniae: incidence, risk factors, and response to therapy in a prospective study. Clin Infect Dis 1995;20:1195-1200
132. Thornsberry C, Ogilvie P, Kahn J, Mauriz Y. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. Diagn Microbiol Infect Dis 1997;29:249-257
133. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32(Suppl 2):S81-S93
134. Farrell DJ, Morrissey I, Bakker S, Buckridge S, Felmingham D. In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations. Antimicrob Agents Chemother 2004;48:3169-3171
135. Brown SD, Farrell DJ. Antibacterial susceptibility among Streptococcus pneumoniae isolated from paediatric and adult patients as part of the PROTEKT US study in 2001-2002. J Antimicrob Chemother 2004;54(Suppl 1):i23-i29
136. Felmingham D, Reinert RR, Hirakata Y, Rodloff A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother 2002;50(Suppl S1):25-37
137. Powis J, McGeer A, Green K, et al. In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002. Antimicrob Agents Chemother 2004;48:3305-3311
138. Hsueh PR, Teng LJ, Wu TL, et al. Telithromycin- and fluoroquinolone- resistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and beta-lactams: SMART program 2001 data. Antimicrob Agents Chemother 2003;47:2145-2151
139. Perez-Trallero E, Fernandez-Mazarrasa C, Garcia-Rey C, et al. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother 2001;45:3334-3340
140. Castanheira M, Gales AC, Mendes RE, Jones RN, Sader HS. Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance Program. Clin Microbiol Infect 2004;10:645-651
141. Mendes C, Kiffer CR, Blosser-Middleton RS, et al. Antimicrobial susceptibility to levofloxacin and other antibacterial agents among common respiratory pathogens-a Brazilian perspective from the GLOBAL Surveillance Initiative 2001-2002. Clin Microbiol Infect 2004;10:521-526
142. Johnson DM, Stilwell MG, Fritsche TR, Jones RN. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003). Diagn Microbiol Infect Dis 2006;56:69-74
143. Doit C, Loukil C, Fitoussi F, Geslin P, Bingen E. Emergence in France of multiple clones of clinical Streptococcus pneumoniae isolates with high-level resistance to amoxicillin. Antimicrob Agents Chemother 1999;43:1480-1483
144. Schito GC, Debbia EA, Marchese A. The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project. J Antimicrob Chemother 2000;46(Suppl T1):3-9
145. Reinert RR, Lutticken R, Bryskier A, Al-Lahham A. Macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes in the pediatric population in Germany during 2000-2001. Antimicrob Agents Chemother 2003;47:489-493
146. Backhaus E, Berg S, Trollfors B, et al. Antimicrobial susceptibility of invasive pneumococcal isolates from a region in south-west Sweden 1998-2001. Scand J Infect Dis 2007;39:19-27
147. Schito GC, Felmingham D. Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEKT 1999-2003). Int J Antimicrob Agents 2005;26:479-485
148. Monaco M, Camilli R, D'Ambrosio F, Del Grosso M, Pantosti A. Evolution of erythromycin resistance in Streptococcus pneumoniae in Italy. J Antimicrob Chemother 2005;55:256-259
149. Marchese A, Gualco L, Cochetti I, et al. Antibiotic susceptibility and serotype distribution in Streptococcus pneumoniae circulating in Italy: results of the SEMPRE surveillance study (2000-2002). Int J Antimicrob Agents 2005;26:138-145
150. Ho P, Yuen K, Yam W, Sai-yin Wong S, Luk W. Changing patterns of susceptibilities of blood, urinary and respiratory pathogens in Hong Kong. J Hosp Infect 1995;31:305-317
151. Ho PL, Que TL, Tsang DN, Ng TK, Chow KH, Seto WH. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1999;43:1310-1313
152. Valles X, Marcos A, Pinart M, et al. Hospitalized community-acquired pneumonia due to Streptococcus pneumoniae: has resistance to antibiotics decreased? Chest 2006;130:800-806
153. Benbachir M, Benredjeb S, Boye CS, et al. Two-year surveillance of antibiotic resistance in Streptococcus pneumoniae in four African cities. Antimicrob Agents Chemother 2001;45:627-629
154. Joloba ML, Bajaksouzian S, Palavecino E, Whalen C, Jacobs MR. High prevalence of carriage of antibiotic-resistant Streptococcus pneumoniae in children in Kampala Uganda. Int J Antimicrob Agents 2001;17:395-400
155. Ramdani-Bouguessa N, Rahal K. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolated in Algiers, Algeria. Antimicrob Agents Chemother 2003;47:824-826
156. Adegbola RA, Hill PC, Secka O, et al. Serotype and antimicrobial susceptibility patterns of isolates of Streptococcus pneumoniae causing invasive disease in The Gambia 1996-2003. Trop Med Int Health 2006;11:1128-1135
157. Sener B, Tunckanat F, Ulusoy S, et al. A survey of antibiotic resistance in Streptococcus pneumoniae and Haemophilus influenzae in Turkey, 2004 2005. J Antimicrob Chemother 2007;60:587-593
158. Gur D, Ozalp M, Sumerkan B, et al. Prevalence of antimicrobial resistance in Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis and Streptococcus pyogenes: results of a multicentre study in Turkey. Int J Antimicrob Agents 2002;19:207-211
159. Heffernan HM, Martin DR, Woodhouse RE, Morgan J, Blackmore TK. Invasive pneumococcal disease in New Zealand 1998-2005: capsular serotypes and antimicrobial resistance. Epidemiol Infect 2008;136:352-359
160. Prospective multicentre hospital surveillance of Streptococcus pneumoniae disease in India. Invasive Bacterial Infection Surveillance (IBIS) Group, International Clinical Epidemiology Network (INCLEN). Lancet 1999;353:1216-1221
161. Saha SK, Rikitomi N, Ruhulamin M, et al. Antimicrobial resistance and serotype distribution of Streptococcus pneumoniae strains causing childhood infections in Bangladesh, 1993 to 1997. J Clin Microbiol 1999;37:798-800
162. Noguchi N, Tano J, Nasu Y, et al. Antimicrobial susceptibilities and distribution of resistance genes for beta-lactams and macrolides in Streptococcus pneumoniae isolated between 2002 and 2004 in Tokyo. Int J Antimicrob Agents 2007;29:26-33
163. Lau YJ, Hsueh PR, Liu YC, et al. Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan. Microb Drug Resist 2006;12:130-135
164. Spika JS, Facklam RR, Plikaytis BD, Oxtoby MJ. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. The Pneumococcal Surveillance Working Group. J Infect Dis 1991;163:1273-1278
165. Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 1990;34:2075-2080
166. Breiman RF, Butler JC, Tenover FC, Elliott JA, Facklam RR. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994;271:1831-1835
167. Butler JC, Hofmann J, Cetron MS, Elliott JA, Facklam RR, Breiman RF. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. J Infect Dis 1996;174:986-993
168. Sahm DF, Jones ME, Hickey ML, Diakun DR, Mani SV, Thornsberry C. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998. J Antimicrob Chemother 2000;45:457-466
169. Jones ME, Staples AM, Critchley I, et al. Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States. Antimicrob Agents Chemother 2000;44:2645-2652
170. Gonzalez BE, Hulten KG, Lamberth L, Kaplan SL, Mason EO Jr. Streptococcus pneumoniae serogroups 15 and 33: an increasing cause of pneumococcal infections in children in the United States after the introduction of the pneumococcal 7-valent conjugate vaccine. Pediatr Infect Dis J 2006;25:301-305
171. Jacobs MR, Good CE, Beall B, Bajaksouzian S, Windau AR, Whitney CG. Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: a quarter century of experience. J Clin Microbiol 2008;46:982-990
172. Pelton SI, Huot H, Finkelstein JA, et al. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007;26:468-472
173. Davidson RJ, Melano R, Forward KR. Antimicrobial resistance among invasive isolates of Streptococcus pneumoniae collected across Canada. Diagn Microbiol Infect Dis 2007;59:75-80
174. Poulakou G, Katsarolis I, Matthaiopoulou I, et al. Nationwide surveillance of Streptococcus pneumoniae in Greece: patterns of resistance and serotype epidemiology. Int J Antimicrob Agents 2007;30:87-92
175. Sahm DF, Karlowsky JA, Kelly LJ, et al. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. Antimicrob Agents Chemother 2001;45:1037-1042
176. Jones RN, Sader HS, Fritsche TR, Pottumarthy S. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis 2007;57:109-116
177. Hsieh YC, Chang KY, Huang YC, et al. Clonal spread of highly beta-lactam-resistant Streptococcus pneumoniae isolates in Taiwan. Antimicrob Agents Chemother 2008;52:2266-2269
178. Richter SS, Heilmann KP, Beekmann SE, Miller NJ, Rice CL, Doern GV. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations. Clin Infect Dis 2005;40:225-235
179. Miller ML, Obert CA, Gao G, Daw NC, Flynn P, Tuomanen E. Cephalosporin-resistant pneumococci and sickle cell disease. Emerg Infect Dis 2005;11:1192-1196
180. John CC. Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review. Clin Infect Dis 1994;18:188-193
181. Klugman KP, Koornhof HJ, Friedland IR. Antibiotic resistance in pneumococcal meningitis. Lancet 1992;340(8816):437-438
182. Ahronheim GA, Reich B, Marks MI. Penicillin-insensitive pneumococci: case report and review. Am J Dis Child 1979;133:187-191
183. Howes VJ, Mitchell RG. Meningitis due to relatively penicillin-resistant pneumococcus. BMJ 1976;1:996
184. Friedland IR, Klugman KP. Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis. Lancet 1992;339:405-408
185. Dagan R, Leibovitz E, Leiberman A, Yagupsky P. Clinical significance of antibiotic resistance in acute otitis media and implication of antibiotic treatment on carriage and spread of resistant organisms. Pediatr Infect Dis J 2000;19(5, Suppl):S57-S65
186. Dowell SF, Butler JC, Giebink GS, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999;18:1-9
187. Kaplan SL, Mason EO Jr, Barson WJ, et al. Outcome of invasive infections outside the central nervous system caused by Streptococcus pneumoniae isolates nonsusceptible to ceftriazone in children treated with beta-lactam antibiotics. Pediatr Infect Dis J 2001;20:392-396
188. Arditi M, Mason EO Jr, Bradley JS, et al. Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. Pediatrics 1998;102:1087-1097
189. Fiore AE, Moroney JF, Farley MM, et al. Clinical outcomes of meningitis caused by Streptococcus pneumoniae in the era of antibiotic resistance. Clin Infect Dis 2000;30:71-77
190. Auburtin M, Porcher R, Bruneel F, et al. Pneumococcal meningitis in the intensive care unit: prognostic factors of clinical outcome in a series of 80 cases. Am J Respir Crit Care Med 2002;165:713-717
191. Tan TQ, Schutze GE, Mason EO Jr, Kaplan SL. Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1994;38:918-923
192. Friedland IR, Klugman KP. Antibiotic-resistant pneumococcal disease in South African children. Am J Dis Child 1992;146:920-923
193. Therapy for children with invasive pneumococcal infections. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics 1997;99:289-299
194. Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. N Engl J Med 1997;336:708-716
195. Leggiadro RJ. The clinical impact of resistance in the management of pneumococcal disease. Infect Dis Clin North Am 1997;11:867-874
196. Frankel RE, Virata M, Hardalo C, Altice FL, Friedland G. Invasive pneumococcal disease: clinical features, serotypes, and antimicrobial resistance patterns in cases involving patients with and without human immunodeficiency virus infection. Clin Infect Dis 1996;23:577-584
197. Kalin M, Ortqvist A, Almela M, et al. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis 2000;182:840-847
198. Marfin AA, Sporrer J, Moore PS, Siefkin AD. Risk factors for adverse outcome in persons with pneumococcal pneumonia. Chest 1995;107:457-462
199. Watanakunakorn C, Greifenstein A, Stroh K, et al. Pneumococcal bacteremia in three community teaching hospitals from 1980 to 1989. Chest 1993;103:1152-1156
200. Afessa B, Greaves WL, Frederick WR. Pneumococcal bacteremia in adults: a 14-year experience in an inner-city university hospital. Clin Infect Dis 1995;21:345-351
201. Castillo EM, Rickman LS, Brodine SK, Ledbetter EK, Kelly C. Streptococcus pneumoniae: bacteremia in an era of penicillin resistance. Am J Infect Control 2000;28:239-243
202. Watanabe H, Sato S, Kawakami K, et al. A comparative clinical study of pneumonia by penicillin-resistant and - sensitive Streptococcus pneumoniae in a community hospital. Respirology 2000;5:59-64
203. Moroney JF, Fiore AE, Harrison LH, et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis 2001;33:797-805
204. Roson B, Carratala J, Tubau F, et al. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone. Microb Drug Resist 2001;7:85-96
205. Wu TT, Hsueh PR, Lee LN, Yang PC, Luh KT. Pneumonia caused by penicillin-nonsusceptible Streptococcus pneumoniae: clinical characteristics, prognostic factors, and outcomes. J Formos Med Assoc 2000;99:18-23
206. Mufson MA, Chan G, Stanek RJ. Penicillin resistance not a factor in outcome from invasive Streptococcus pneumoniae community-acquired pneumonia in adults when appropriate empiric therapy is started. Am J Med Sci 2007;333:161-167
207. Falco V, Almirante B, Jordano Q, et al. Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains? J Antimicrob Chemother 2004;54:481-488
208. Tleyjeh IM, Tlaygeh HM, Hejal R, Montori VM, Baddour LM. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2006;42:788-797
209. Lujan M, Gallego M, Fontanals D, Mariscal D, Rello J. Prospective observational study of bacteremic pneumococcal pneumonia: effect of discordant therapy on mortality. Crit Care Med 2004;32:625-631
210. Bradley JS, Connor JD. Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to beta-lactam antibiotics. Pediatr Infect Dis J 1991;10:871-873
211. Viladrich PF, Gudiol F, Linares J, Rufi G, Ariza J, Pallares R. Characteristics and antibiotic therapy of adult meningitis due to penicillin-resistant pneumococci. Am J Med 1988;84:839-846
212. Friedland IR, Shelton S, Paris M, et al. Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J 1993;12:196-200
213. Lonks JR, Durkin MR, Meyerhoff AN, Medeiros AA. Meningitis due to ceftriaxone-resistant Streptococcus pneumoniae. N Engl J Med 1995;332:893-894
214. Guibert M, Chahime H, Petit J, Odievre M, Labrune P. Failure of cefotaxime treatment in two children with meningitis caused by highly penicillin-resistant Streptococcus pneumoniae. Acta Paediatr 1995;84:831-833
215. Greene GS, Demasi R. Case report: penicillin-resistant pneumococcal meningitis: navigating a therapeutic mine-field. Am J Med Sci 1996;311:180-185
216. Pacheco TR, Cooper CK, Hardy DJ, Betts RF, Bonnez W. Failure of cefotaxime treatment in an adult with Streptococcus pneumoniae meningitis. Am J Med 1997;102:303-305
217. Viladrich PF, Cabellos C, Pallares R, et al. High doses of cefotaxime in treatment of adult meningitis due to Streptococcus pneumoniae with decreased susceptibilities to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1996;40:218-220
218. Sacho H, Klugman KP, Koornhof HJ, Ruff P. Community-acquired pneumonia in an adult due to a multiply-resistant pneumococcus. J Infect 1987;14:188-189
219. Buckingham SC, Brown SP, Joaquin VH. Breakthrough bacteremia and meningitis during treatment with cephalosporins parenterally for pneumococcal pneumonia. J Pediatr 1998;132:174-176
220. Dowell SF, Smith T, Leversedge K, Snitzer J. Failure of treatment of pneumonia associated with highly resistant pneumococci in a child. Clin Infect Dis 1999;29:462-463
221. Silverstein M, Bachur R, Harper MB. Clinical implications of penicillin and ceftriaxone resistance among children with pneumococcal bacteremia. Pediatr Infect Dis J 1999;18:35-41
222. Klugman KP, Lonks JR. Hidden epidemic of macrolide-resistant pneumococci. Emerg Infect Dis 2005;11:802-807
223. Geslin P, Buu-Hoi A, Fremaux A, Acar JF. Antimicrobial resistance in Streptococcus pneumoniae: an epidemiological survey in France, 1970-1990. Clin Infect Dis 1992;15:95-98
224. Verhaegen J, Glupczynski Y, Verbist L, et al. Capsular types and antibiotic susceptibility of pneumococci isolated from patients in Belgium with serious infections, 1980-1993. Clin Infect Dis 1995;20:1339-1345
225. Zhanel GG, Dueck M, Hoban DJ, et al. Review of macrolides and ketolides: focus on respiratory tract infections. Drugs 2001;61:443-498
226. Edelstein PH. Pneumococcal resistance to macrolides, lincosamides, ketolides, and streptogramin B agents: molecular mechanisms and resistance phenotypes. Clin Infect Dis 2004;38(Suppl 4):S322-S327
227. Tait-Kamradt A, Davies T, Appelbaum PC, et al. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother 2000;44:3395-3401
228. Cerda Zolezzi P, Laplana LM, Calvo CR, Cepero PG, Erazo MC, Gomez-Lus R. Molecular basis of resistance to macrolides and other antibiotics in commensal viridans group streptococci and Gemella spp. and transfer of resistance genes to Streptococcus pneumoniae. Antimicrob Agents Chemother 2004;48:3462-3467
229. Wierzbowski AK, Swedlo D, Boyd D, et al. Molecular epidemiology and prevalence of macrolide efflux genes mef(A) and mef(E) in Streptococcus pneumoniae obtained in Canada from 1997 to 2002. Antimicrob Agents Chemother 2005;49:1257-1261
230. Farrell DJ, Jenkins SG. Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002. J Antimicrob Chemother 2004;54(Suppl 1):i17-i22
231. Amezaga MR, Carter PE, Cash P, McKenzie H. Molecular epidemiology of erythromycin resistance in Streptococcus pneumoniae isolates from blood and noninvasive sites. J Clin Microbiol 2002;40:3313-3318
232. Montanari MP, Mingoia M, Cochetti I, Varaldo PE. Phenotypes and genotypes of erythromycin-resistant pneumococci in Italy. J Clin Microbiol 2003;41:428-431
233. Del Grosso M, Iannelli F, Messina C, et al.Macrolide efflux genes mef(A) and mef(E) are carried by different genetic elements in Streptococcus pneumoniae. J Clin Microbiol 2002;40:774-778
234. Canu A, Malbruny B, Coquemont M, Davies TA, Appelbaum PC, Leclercq R. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2002;46:125-131
235. Shortridge VD, Doern GV, Brueggemann AB, Beyer JM, Flamm RK. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin Infect Dis 1999;29:1186-1188
236. Farrell DJ, Douthwaite S, Morrissey I, et al. Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study. Antimicrob Agents Chemother 2003;47:1777-1783
237. Morosini MI, Loza E, del Campo R, Almaraz F, Baquero F, Canton R. Fluoroquinolone-resistant Streptococcus pneumoniae in Spain: activities of garenoxacin against clinical isolates including strains with altered topoisomerases. Antimicrob Agents Chemother 2003;47:2692-2695
238. Bingen E, Doit C, Loukil C, et al. Activity of telithromycin against penicillin-resistant Streptococcus pneumoniae isolates recovered from French children with invasive and non-invasive infections. Antimicrob Agents Chemother 2003;47:2345-2347
239. Tiemei Z, Xiangqun F, Youning L. Resistance phenotypes and genotypes of erythromycin-resistant Streptococcus pneumoniae isolates in Beijing and Shenyang, China. Antimicrob Agents Chemother 2004;48:4040-4041
240. Isozumi R, Ito Y, Ishida T, et al. Genotypes and related factors reflecting macrolide resistance in pneumococcal pneumonia infections in Japan. J Clin Microbiol 2007;45:1440-1446
241. Jones ME, Sahm DF, Martin N, et al. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season. Antimicrob Agents Chemother 2000;44:462-466
242. Pihlajamaki M, Jalava J, Huovinen P, Kotilainen P. Antimicrobial resistance of invasive pneumococci in Finland in 1999-2000. Antimicrob Agents Chemother 2003;47:1832-1835
243. Reinert RR, Al-Lahham A, Lemperle M, et al. Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J Antimicrob Chemother 2002;49:61-68
244. Tait-Kamradt A, Davies T, Cronan M, Jacobs MR, Appelbaum PC, Sutcliffe J. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother 2000;44:2118-2125
245. Pihlajamaki M, Kataja J, Seppala H, et al. Ribosomal mutations in Streptococcus pneumoniae clinical isolates. Antimicrob Agents Chemother 2002;46:654-658
246. Dias R, Canica M. Emergence of invasive erythromycin-resistant Streptococcus pneumoniae strains in Portugal: contribution and phylogenetic relatedness of serotype 14. J Antimicrob Chemother 2004;54:1035-1039
247. Sweeney MT, Zurenko GE. In vitro activities of linezolid combined with other antimicrobial agents against staphylococci, enterococci, pneumococci, and selected gram-negative organisms. Antimicrob Agents Chemother 2003;47:1902-1906
248. Anderegg TR, Sader HS, Fritsche TR, Ross JE, Jones RN. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. Int J Antimicrob Agents 2005;26:13-21
249. Metlay JP, Fishman NO, Joffe MM, Kallan MJ, Chittams JL, Edelstein PH. Macrolide resistance in adults with bacteremic pneumococcal pneumonia. Emerg Infect Dis 2006;12:1223-1230
250. Barkai G, Greenberg D, Givon-Lavi N, Dreifuss E, Vardy D, Dagan R. Community prescribing and resistant Streptococcus pneumoniae. Emerg Infect Dis 2005;11:829-837
251. Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J Infect 2004;48:56-65
252. Ortega M, Marco F, Soriano A, Garcia E, Martinez JA, Mensa J. Lack of vancomycin tolerance in Streptococcus pneumoniae strains isolated in Barcelona, Spain, from 1999 to 2001. Antimicrob Agents Chemother 2003;47:1976-1978
253. Kanavaki S, Karabela S, Marinis E, Legakis NJ. Antibiotic resistance of clinical isolates of Streptococcus pneumoniae in Greece. J Clin Microbiol 1994;32:3056-3058
254. Ednie LM, Visalli MA, Jacobs MR, Appelbaum PC. Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci. Antimicrob Agents Chemother 1996;40:1950-1952
255. Friedland IR, McCracken GH Jr. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994;331:377-382
256. Arri SJ, Fluegge K, Mueller U, Berner R. Antibiotic resistance patterns among respiratory pathogens at a German university children's hospital over a period of 10 years. Eur J Pediatr 2006;165:9-13
257. Ip M, Lyon DJ, Yung RW, Chan C, Cheng AF. Macrolide resistance in Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 2001;45:1578-1580
258. Hsueh PR, Luh KT. Antimicrobial resistance in Streptococcus pneumoniae, Taiwan. Emerg Infect Dis 2002;8:1487-1491
259. Bergan T, Gaustad P, Hoiby EA, et al. Antibiotic resistance of pneumococci in Norway. Int J Antimicrob Agents 1998;10:77-81
260. Berner R. Antimicrobial susceptibility patterns of Streptococcus pneumoniae and Haemophilus influenzae in a German pediatric hospital, 1993 to 1997. Pediatr Infect Dis J 1998;17:925-927
261. Reinert RR, Queck A, Kaufhold A, Kresken M, Lutticken R. Antimicrobial resistance and type distribution of Streptococcus pneumoniae isolates causing systemic infections in Germany, 1992-1994. Clin Infect Dis 1995;21:1398-1401
262. Mittermayer H, Jebelean C, Binder L, Haditsch M, Watschinger R. Antibiotic susceptibility of pneumococci isolated in Austria over a four-year period. Eur J Clin Microbiol Infect Dis 1996;15:817-820
263. Boswell TC, Frodsham D, Nye KJ, Smith EG. Antibiotic resistance and serotypes of Streptococcus pneumoniae at Birmingham Public Health Laboratory, 1989-94. J Infect 1996;33:17-22
264. Aszkenasy OM, George RC, Begg NT. Pneumococcal bacteraemia and meningitis in England and Wales 1982 to 1992. Commun Dis Rep CDR Rev 1995;5:R45-R50
265. Klugman KP, Capper T, Widdowson CA, Koornhof HJ, Moser W. Increased activity of 16-membered lactone ring macrolides against erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae: characterization of South African isolates. J Antimicrob Chemother 1998;42:729-734
266. Dagan R, Melamed R, Muallem M, Piglansky L, Yagupsky P. Nasopharyngeal colonization in southern Israel with antibiotic-resistant pneumococci during the first 2 years of life: relation to serotypes likely to be included in pneumococcal conjugate vaccines. J Infect Dis 1996;174:1352-1355
267. Barry AL, Pfaller MA, Fuchs PC, Packer RR. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993. Antimicrob Agents Chemother 1994;38:2419-2425
268. Mason EO Jr, Lamberth LB, Wald ER, Bradley JS, Barson WJ, Kaplan SL. In vitro activities of cethromycin (ABT-773), a new ketolide, against Streptococcus pneumoniae strains that are not susceptible to penicillin or macrolides. Antimicrob Agents Chemother 2003;47:166-169
269. Karchmer AW. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US - an update. Clin Infect Dis 2004;39(Suppl 3):S142-S150
270. Farrell DJ, File TM, Jenkins SG. Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US Study. J Clin Microbiol 2007;45:290-293
271. Johnston NJ, De Azavedo JC, Kellner JD, Low DE. Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998;42:2425-2426
272. Zhanel GG, Karlowsky JA, Palatnick L, Vercaigne L, Low DE, Hoban DJ. Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: results of a Canadian national surveillance study. The Canadian Respiratory Infection Study Group. Antimicrob Agents Chemother 1999;43:2504-2509
273. Felmingham D, Washington J. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens: findings of the Alexander Project 1992-1996. J Chemother 1999;11(Suppl 1):5-21
274. Louie M, Louie L, Papia G, Talbot J, Lovgren M, Simor AE. Molecular analysis of the genetic variation among penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae serotypes in Canada. J Infect Dis 1999;179:892-900
275. Duchin JS, Breiman RF, Diamond A, et al. High prevalence of multidrug-resistant Streptococcus pneumoniae among children in a rural Kentucky community. Pediatr Infect Dis J 1995;14:745-750
276. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002;35:556-564
277. Van Kerkhoven D, Peetermans WE, Verbist L, Verhaegen J. Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams. J Antimicrob Chemother 2003;51:691-696
278. McGee L, Klugman KP, Wasas A, Capper T, Brink A. Serotype 19f multiresistant pneumococcal clone harboring two erythromycin resistance determinants (erm(B) and mef(A)) in South Africa. Antimicrob Agents Chemother 2001;45:1595-1598
279. McGee L, Wang H, Wasas A, Huebner R, Chen M, Klugman KP. Prevalence of serotypes and molecular epidemiology of Streptococcus pneumoniae strains isolated from children in Beijing, China: identification of two novel multiply-resistant clones. Microb Drug Resist 2001;7:55-63
280. Ko KS, Song JH. Evolution of erythromycin-resistant Streptococcus pneumoniae from Asian countries that contains erm(B) and mef(A) genes. J Infect Dis 2004;190:739-747
281. Farrell DJ, Morrissey I, Bakker S, Morris L, Buckridge S, Felmingham D. Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B)- and mef(A)-mediated macrolide resistance. J Clin Microbiol 2004;42:764-768
282. Musher DM, Dowell ME, Shortridge VD, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002;346:630-631
283. Rzeszutek M, Wierzbowski A, Hoban DJ, Conly J, Bishai W, Zhanel GG. A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae. Int J Antimicrob Agents 2004;24:95-104
284. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003;36:389-395
285. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001;161:1837-1842
286. Zhanel GG, Johanson C, Laing N, Hisanaga T, Wierzbowski A, Hoban DJ. Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary. Antimicrob Agents Chemother 2005;49:1943-1948
287. Lonks JR, Goldmann DA. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections. Clin Infect Dis 2005;40:1657-1664
288. Syrogiannopoulos GA, Grivea IN, Ednie LM, et al. Antimicrobial susceptibility and macrolide resistance inducibility of Streptococcus pneumoniae carrying erm(A), erm(B), or mef(A). Antimicrob Agents Chemother 2003;47:2699-2702
289. Jorgensen JH, Crawford SA, McElmeel ML, Whitney CG. Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2004;48:605-607
290. Morrissey I, Farrell DJ, Bakker S, Buckridge S, Felmingham D. Molecular characterization and antimicrobial susceptibility of fluoroquinolone-resistant or -susceptible Streptococcus pneumoniae from Hong Kong. Antimicrob Agents Chemother 2003;47:1433-1435
291. Stratton CW, Brown SD. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000-2001. Clin Ther 2004;26:522-530
292. Farrell DJ, Felmingham D. Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003. Antimicrob Agents Chemother 2004;48:1882-1884
293. Perez-Trallero E, Marimon JM, Iglesias L, Larruskain J. Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates. Emerg Infect Dis 2003;9:1159-1162
294. Al-Lahham A, Appelbaum PC, van der Linden M, Reinert RR. Telithromycin-nonsusceptible clinical isolates of Streptococcus pneumoniae from Europe. Antimicrob Agents Chemother 2006;50:3897-3900
295. Zervos MJ, Hershberger E, Nicolau DP, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis 2003;37:1643-1648
296. Paterson DL, Mulazimoglu L, Casellas JM, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000;30:473-478
297. Saurina G, Quale JM, Manikal VM, Oydna E, Landman D. Antimicrobial resistance in Enterobacteriaceae in Brooklyn, NY: epidemiology and relation to antibiotic usage patterns. J Antimicrob Chemother 2000;45:895-898
298. Thomson CJ. The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective. J Antimicrob Chemother 1999;43(Suppl A):31-40
299. de la Campa AG, Ferrandiz MJ, Tubau F, Pallares R, Manresa F, Linares J. Genetic characterization of fluoroquinolone-resistant Streptococcus pneumoniae strains isolated during ciprofloxacin therapy from a patient with bronchiectasis. Antimicrob Agents Chemother 2003;47:1419-1422
300. Perez-Trallero E, Garcia-Arenzana JM, Jimenez JA, Peris A. Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin. Eur J Clin Microbiol Infect Dis 1990;9:905-906
301. Ena J, Lopez-Perezagua MM, Martinez-Peinado C, Cia-Barrio MA, Ruiz-Lopez I. Emergence of ciprofloxacin resistance in Escherichia coli isolates after widespread use of fluoroquinolones. Diagn Microbiol Infect Dis 1998;30:103-107
302. Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 2002;62:13-59
303. Adam HJ, Schurek KN, Nichol KA, et al. Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005. Antimicrob Agents Chemother 2007;51:198-207
304. Li X, Zhao X, Drlica K. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin. Antimicrob Agents Chemother 2002;46:522-524
305. Fernandez-Moreira E, Balas D, Gonzalez I, de la Campa AG. Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins. Microb Drug Resist 2000;6:259-267
306. Balsalobre L, de la Campa AG. Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes. Antimicrob Agents Chemother 2008;52:822-830
307. Pan XS, Fisher LM. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones. Antimicrob Agents Chemother 1999;43:1129-1136
308. Davies TA, Evangelista A, Pfleger S, Bush K, Sahm DF, Goldschmidt R. Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000. Antimicrob Agents Chemother 2002;46:119-124
309. Smith HJ, Walters M, Hisanaga T, Zhanel GG, Hoban DJ. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates. Antimicrob Agents Chemother 2004;48:3954-3958
310. Martinez-Garriga B, Vinuesa T, Hernandez-Borrell J, Vinas M. The contribution of efflux pumps to quinolone resistance in Streptococcus pneumoniae clinical isolates. Int J Med Microbiol 2007;297:187-195
311. Jumbe NL, Louie A, Miller MH, et al. Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2006;50:310-317
312. Ho PL, Tse WS, Tsang KW, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis 2001;32:701-707
313. Perez-Trallero E, Marimon JM, Gonzalez A, Ercibengoa M, Larruskain J. In vivo development of high-level fluoroquinolone resistance in Streptococcus pneumoniae in chronic obstructive pulmonary disease. Clin Infect Dis 2005;41:560-564
314. Kupronis BA, Richards CL, Whitney CG. Invasive pneumococcal disease in older adults residing in long-term care facilities and in the community. J Am Geriatr Soc 2003;51:1520-1525
315. Deshpande LM, Sader HS, Debbia E, Nicoletti G, Fadda G, Jones RN. Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004). Diagn Microbiol Infect Dis 2006;54:157-164
316. Johnson AP, Sheppard CL, Harnett SJ, et al. Emergence of a fluoroquinolone-resistant strain of Streptococcus pneumoniae in England. J Antimicrob Chemother 2003;52:953-960
317. Goldsmith CE, Moore JE, Murphy PG, Ambler JE. Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland. J Antimicrob Chemother 1998;41:420-421
318. Schmitz FJ, Perdikouli M, Beeck A, Verhoef J, Fluit AC. Molecular surveillance of macrolide, tetracycline and quinolone resistance mechanisms in 1191 clinical European Streptococcus pneumoniae isolates. Int J Antimicrob Agents 2001;18:433-436
319. Nagai K, Appelbaum PC, Davies TA, et al. Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 pneumococci from 10 central and Eastern European countries. Antimicrob Agents Chemother 2002;46:371-377
320. Jones ME, Blosser-Middleton RS, Critchley IA, Karlowsky JA, Thornsberry C, Sahm DF. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001. Clin Microbiol Infect 2003;9:590-599
321. Garcia-Rey C, Aquilar L, Baquero F. Influences of different factors on prevalence of ciprofloxacin resistance in Streptococcus pneumoniae in Spain. Antimicrob Agents Chemother 2000;44:3481-3482
322. von Gottberg A, Klugman KP, Cohen C, et al. Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. Lancet 2008;371:1108-1113
323. Gosbell IB, Fernandes LA, Fernandes CJ. In vitro antibacterial activity of beta-lactams and non-beta-lactams against Streptococcus pneumoniae isolates from Sydney, Australia. Pathology 2006;38:343-348
324. Song JH, Oh WS, Kang CI, et al. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. Int J Antimicrob Agents 2008;31:107-114
325. Yamaguchi K, Ohno A. Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: a longitudinal analysis from 1994 to 2002. Diagn Microbiol Infect Dis 2005;52:135-143
326. Chiu SS, Ho PL, Chow FK, Yuen KY, Lau YL. Nasopharyngeal carriage of antimicrobial-resistant Streptococcus pneumoniae among young children attending 79 kindergartens and day care centers in Hong Kong. Antimicrob Agents Chemother 2001;45:2765-2770
327. Jones RN, Pfaller MA. Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999). J Clin Microbiol 2000;38:4298-4299
328. Pottumarthy S, Fritsche TR, Sader HS, Stilwell MG, Jones RN. Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents. Int J Antimicrob Agents 2005;25:282-289
329. Quale J, Landman D, Ravishankar J, Flores C, Bratu S. Streptococcus pneumoniae, Brooklyn, New York: fluoroquinolone resistance at our doorstep. Emerg Infect Dis 2002;8:594-597
330. Bhavnani S, Hammel JP, Jones RN, et al. Relationship between increased levofloxacin use and decreased susceptibility to Streptococcus pneumonia: report from the ARREST Program [abstract K-1397]. In: Program and Abstracts of the 43rd International Conference on Antimicrobial QAgents and Chemotherapy; Washington, DC: American Society for Microbiology; 2003:383
331. Lim S, Bast D, McGeer A, de Azavedo J, Low DE. Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg Infect Dis 2003;9:833-837
332. Davies TA, Yee YC, Bush K, Sahm D, Evangelista A, Goldschmidt R. Effects of the 7-valent pneumococcal conjugate vaccine on U.S. levofloxacin-resistant Streptococcus pneumoniae. Microb Drug Resist 2008;14:187-196
333. Perez-Trallero E, Garcia-Rey C, Martin-Sanchez AM, Aguilar L, Garcia-de-Lomas J, Ruiz J. Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain. Antimicrob Agents Chemother 2002;46:2665-2667
334. Zhanel GG, Walkty A, Nichol K, Smith H, Noreddin A, Hoban DJ. Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada. Diagn Microbiol Infect Dis 2003;45:63-67
335. Davies TA, Yee YC, Goldschmidt R, Bush K, Sahm DF, Evangelista A. Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003). J Antimicrob Chemother 2006;57:437-442
336. Pletz MW, Shergill AP, McGee L, Beall B, Whitney CG, Klugman KP. Prevalence of first-step mutants among levofloxacin-susceptible invasive isolates of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 2006;50:1561-1563
337. McGee L, Goldsmith CE, Klugman KP. Fluoroquinolone resistance among clinical isolates of Streptococcus pneumoniae belonging to international multiresistant clones. J Antimicrob Chemother 2002;49:173-176
338. Canton R, Morosini M, Enright MC, Morrissey I. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J Antimicrob Chemother 2003;52:944-952
339. Perez-Trallero E, Marimon JM, Gonzalez A, Iglesias L. Spain14-5 international multiresistant Streptococcus pneumoniae clone resistant to fluoroquinolones and other families of antibiotics. J Antimicrob Chemother 2003;51:715-719
340. Carter RJ, Sorenson G, Heffernan R, et al. Failure to control an outbreak of multidrug-resistant Streptococcus pneumoniae in a long-term-care facility: emergence and ongoing transmission of a fluoroquinolone-resistant strain. Infect Control Hosp Epidemiol 2005;26:248-255
341. Fry AM, Udeagu CC, Soriano-Gabarro M, et al. Persistence of fluoroquinolone-resistant, multidrug-resistant Streptococcus pneumoniae in a long-term-care facility: efforts to reduce intrafacility transmission. Infect Control Hosp Epidemiol 2005;26:239-247
342. Ambrose PG, Bhavnani SM, Owens RC Jr. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am 2003;17:529-543
343. Jones RN, Rubino CM, Bhavnani SM, Ambrose PG. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob Agents Chemother 2003;47:292-296
344. Allen GP, Kaatz GW, Rybak MJ. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003;47:2606-2614
345. Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001;45:433-438
346. Smith HJ, Noreddin AM, Siemens CG, et al. Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics. Antimicrob Agents Chemother 2004;48:3630-3635
347. Bast DJ, Low DE, Duncan CL, et al. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob Agents Chemother 2000;44:3049-3054
348. Hovde LB, Simonson DA, Rotschafer JC. Frequency of 1st-and 2nd-step topoisomerase mutations in Streptococcus pneumoniae following levofloxacin and moxifloxacin exposure. Diagn Microbiol Infect Dis 2008;60:295-299
349. Kays MB, Smith DW, Wack ME, Denys GA. Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. Pharmacotherapy 2002;22:395-399
350. Ross JJ, Worthington MG, Gorbach SL. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;347:65-67author reply 67
351. Anderson KB, Tan JS, File TM Jr, DiPersio JR, Willey BM, Low DE. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 2003;37:376-381
352. Pletz MW, McGee L, Burkhardt O, Lode H, Klugman KP. Ciprofloxacin treatment failure in a patient with resistant Streptococcus pneumoniae infection following prior ciprofloxacin therapy. Eur J Clin Microbiol Infect Dis 2005;24:58-60
353. Roson B, Carratala J, Fernandez-Sabe N, Tubau F, Manresa F, Gudiol F. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004;164:502-508
354. Fuller JD, Low DE. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis 2005;41:118-121
355. Fluit AC, Florijn A, Verhoef J, Milatovic D. Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob Agents Chemother 2005;49:1636-1638
356. Izdebski R, Sadowy E, Fiett J, Grzesiowski P, Gniadkowski M, Hryniewicz W. Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland. Antimicrob Agents Chemother 2007;51:1155-1163
357. Erdem H, Pahsa A. Antibiotic resistance in pathogenic Streptococcus pneumoniae isolates in Turkey. J Chemother 2005;17:25-30
358. Jenkins SG, Farrell DJ, Patel M, Lavin BS. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3. J Infect 2005;51:355-363
359. Wierzbowski A, Nichol K, DeCorby M, Hoban DJ, Zhanel G. Streptococcus pneumoniae in Canadian intensive care units: prevalence and antibiotic resistance results obtained during 2005 and 2006 Canadian Intensive Care Unit Surveillance Study (CAN-ICU). Vancouver, BC: Association of Medical Microbiology and Infectious Diseases of Canada (AMMI); 2008
360. Karpanoja P, Nyberg ST, Bergman M, et al. Connection between trimethoprim-sulfamethoxazole use and resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother 2008;52:2480-2485
361. Zarakolu P, Soyletir G, Gur D, Unal S. Antimicrobial resistance patterns of respiratory pathogens: a local report from Turkey. Clin Microbiol Infect 2003;9:1257-1258
362. Novak R, Henriques B, Charpentier E, Normark S, Tuomanen E. Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature 1999;399:590-593
363. McCullers JA, English BK, Novak R. Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. J Infect Dis 2000;181:369-373
364. Henriques Normark B, Novak R, Ortqvist A, Kallenius G, Tuomanen E, Normark S. Clinical isolates of Streptococcus pneumoniae that exhibit tolerance of vancomycin. Clin Infect Dis 2001;32:552-558
365. Gillis LM, White HD, Whitehurst A, Sullivan DC. Vancomycin-tolerance among clinical isolates of Streptococcus pneumoniae in Mississippi during 1999-2001. Am J Med Sci 2005;330:65-68
366. Cha R, Rybak MJ. Linezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003;47:1984-1987
367. Rodriguez-Cerrato V, McCoig CC, Saavedra J, et al. Garenoxacin (BMS-284756) and moxifloxacin in experimental meningitis caused by vancomycin-tolerant pneumococci. Antimicrob Agents Chemother 2003;47:211-215
368. Martinez-Lacasa J, Cabellos C, Martos A, et al. Experimental study of the efficacy of vancomycin, rifampicin and dexamethasone in the therapy of pneumococcal meningitis. J Antimicrob Chemother 2002;49:507-513
369. Linares J, Pallares R, Alonso T, et al. Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990). Clin Infect Dis 1992;15:99-105
370. Marchese A, Mannelli S, Tonoli E, Gorlero F, Toni M, Schito GC. Prevalence of antimicrobial resistance in Streptococcus pneumoniae circulating in Italy: results of the Italian Epidemiological Observatory Survey (1997-1999). Microb Drug Resist 2001;7:277-287
371. Ferrandiz MJ, Ardanuy C, Linares J, et al. New mutations and horizontal transfer of rpoB among rifampin-resistant Streptococcus pneumoniae from four Spanish hospitals. Antimicrob Agents Chemother 2005;49:2237-2245
372. Restrepo MI, Velez JA, McElmeel ML, Whitney CG, Jorgensen JH. Activity of daptomycin against recent North American isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2003;47:2974-2977
373. Spangler SK, Jacobs MR, Appelbaum PC. Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 1996;40:481-484
374. Fluit AC, Schmitz FJ, Verhoef J, Milatovic D. In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants. Antimicrob Agents Chemother 2004;48:1007-1011
375. Cottagnoud P, Pfister M, Acosta F, et al. Daptomycin is highly efficacious against penicillin-resistant and penicillin-and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2004;48:3928-3933
376. Cottagnoud P, Pfister M, Cottagnoud M, Acosta F, Tauber MG. Activities of ertapenem, a new long-acting carbapenem, against penicillin-sensitive or -resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2003;47:1943-1947
377. Cabellos C, Fernandez A, Maiques JM, et al. Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 2003;47:1907-1911
378. Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 2004;64:63-88
379. Denys GA, Koch KM, Dowzicky MJ. Distribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Am J Infect Control 2007;35:521-526
380. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000;30:100-121
381. Feikin DR, Klugman KP. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis 2002;35:547-555
382. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737-1746
383. Pelton SI. The decline in invasive pneumococcal disease. Pediatrics 2004;113(3 Pt 1):617-618
384. Kaplan SL, Mason EO Jr, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 2004;113(3 Pt 1):443-449
385. Talbot TR, Poehling KA, Hartert TV, et al. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2004;39:641-648
386. Dagan R, Givon-Lavi N, Zamir O, et al. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis 2002;185:927-936
387. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001;344:403-409
388. Temime L, Guillemot D, Boelle PY. Short- and long-term effects of pneumococcal conjugate vaccination of children on penicillin resistance. Antimicrob Agents Chemother 2004;48:2206-2213
389. Regelmann WE. A pain in the ear: what has the 7-valent conjugated pneumococcal vaccine done to reduce the incidence of acute otitis media? Clin Infect Dis 2005;40:1745-1747
390. Park SY, Moore MR, Bruden DL, et al. Impact of conjugate vaccine on transmission of antimicrobial-resistant Streptococcus pneumoniae among Alaskan children. Pediatr Infect Dis J 2008;27:335-340
391. McGee L. The coming of age of niche vaccines? Effect of vaccines on resistance profiles in Streptococcus pneumoniae Curr Opin Microbiol 2007;10:473-478
392. Choi EH, Kim SH, Kim SJ, et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis 2008;14:275-281
393. Mera R, Miller LA, Fritsche TR, Jones RN. Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb Drug Resist 2008;14:101-107
394. Hanage WP, Huang SS, Lipsitch M, et al. Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J Infect Dis 2007;195:347-352